Key result
Combined immunosuppressive therapy successfully treated a 46-year-old woman who developed giant cell myocarditis following COVID-19 infection, leading to clinical and echocardiographic recovery.
Why the study?
SARS-CoV-2 can cause multi-organ impairment, and acute myocarditis is a serious and fatal complication of COVID-19.
Case Report (n=1)
No
This case report demonstrates that COVID-19 can trigger giant cell myocarditis, particularly in patients with a background of autoimmune disorders, which can be successfully managed with combined immunosuppressive therapy.
May support immunosuppression in post-COVID giant cell myocarditis; leaves open efficacy in prospective studies.
It has been shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by coronavirus disease 2019 (COVID-19), can lead to multi-organ impairment including cardiac involvement and immunological problems. Acute myocarditis is one of serious and fatal complications of COVID-19. In this case report, we present a 46-year-old lady with a history of lichen planus dermatitis who has developed a rapidly progressive heart failure after an episode of COVID-19. The pathologic examination of her endomyocardial biopsy specimens was compatible with GCM, and she was successfully treated with a combined immunosuppressive therapy regimen.
No takes yet. Share an insight, caveat, or question.
Amiri et al. (2022) conducted a case report in Giant cell myocarditis following COVID-19 (n=1). Combined immunosuppressive therapy was evaluated on Clinical and echocardiographic improvement. Combined immunosuppressive therapy successfully treated a 46-year-old woman who developed giant cell myocarditis following COVID-19 infection, leading to clinical and echocardiographic recovery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: